Biotech · Private company
MorphoSys AG
Track this companyFree. Adds MorphoSys AG to your Dealase workspace and tells you when its record changes.
Clinical trials90 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- IdelalisibPhase 2 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- LenalidomidePhase 2 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- MOR00208 (formerly Xmab 5574)Phase 2 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TafasitamabPhase 2 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TafasitamabPhase 2 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- Tafasitamab plus lenalidomidePhase 1 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaPHASE1_PHASE2 · TERMINATED · started Aug 4, 2023ClinicalTrials.gov NCT05626322 · fetched Nov 12, 2026
- Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLCOMPLETED · started Apr 1, 2020ClinicalTrials.gov NCT04697160 · fetched Nov 12, 2026
- Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCLPHASE1 · COMPLETED · started Dec 11, 2019ClinicalTrials.gov NCT04134936 · fetched Nov 12, 2026
- Lenalidomide Monotherapy in R/R DLBCLCOMPLETED · started Apr 12, 2019ClinicalTrials.gov NCT04150328 · fetched Nov 12, 2026
- Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid TumorsPHASE1 · COMPLETED · started May 26, 2017ClinicalTrials.gov NCT03102320 · fetched Nov 12, 2026
- Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiPHASE2 · COMPLETED · started Nov 1, 2016ClinicalTrials.gov NCT02639910 · fetched Nov 12, 2026
- Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCLPHASE2 · COMPLETED · started Mar 29, 2016ClinicalTrials.gov NCT02399085 · fetched Nov 12, 2026
- Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLLPHASE2 · COMPLETED · started Jan 17, 2014ClinicalTrials.gov NCT02005289 · fetched Nov 12, 2026
- Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)PHASE2 · COMPLETED · started Apr 23, 2013ClinicalTrials.gov NCT01685008 · fetched Nov 12, 2026